Next challenger? MetaVia pushes obesity drug to higher doses

All patients have reached the highest planned doses of DA-1726, keeping the company’s obesity program on track for late-2026 data. The first wave of blockbuster obesity drugs changed the conversation by helping people feel full sooner. They work remarkably well for many patients, but they’ve also created a new expectation: successful weight loss often comes […] The post Next challenger? MetaVia pushes obesity drug to higher doses appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.